RLMD - Relmada Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
40.66
+0.36 (+0.89%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close40.30
Open40.30
Bid0.00 x 1800
Ask0.00 x 800
Day's Range40.25 - 41.00
52 Week Range4.60 - 48.00
Volume226,899
Avg. Volume152,496
Market Cap578.055M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Top Pharmaceutical Stocks for Q1 2020
    Investopedia

    Top Pharmaceutical Stocks for Q1 2020

    The pharmaceutical business is part of the larger healthcare sector. Pharmaceutical products may be generic, such as those used for common ailments like the flu and colds, or branded, patented drugs used for treating rare diseases including certain types of cancers. Among the best-known pharmaceutical companies are Eli Lilly & Co. (LLY) and Merck & Co. (MRK).

  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • Relmada Therapeutics Announces Proposed Public Offering of Common Stock
    PR Newswire

    Relmada Therapeutics Announces Proposed Public Offering of Common Stock

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

  • What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?

    The big shareholder groups in Relmada Therapeutics, Inc. (NASDAQ:RLMD) have power over the company. Institutions often...

  • Benzinga

    Relmada Shares Hit 4-Year High As Depression Drug Aces Midstage Trial

    New York-based Relmada released top-line data from a Phase 2 study that evaluated its REL-1017-202, chemically dextromethadone, in 25mg once a day and 50mg daily doses as an adjunctive treatment in patients with treatment-resistant depression, or TRD. The 62 subjects enrolled in the study had an average age of 49.2 years, an average Hamilton Depression Rating Scale score of 25.3 and an average Montgomery-Asberg Depression Rating Scale score of 34, reflecting severe depression.